145 related articles for article (PubMed ID: 25391489)
1. The potential for a generally applicable mapping model between QLQ-C30 and SF-6D in patients with different cancers: a comparison of regression-based methods.
Kontodimopoulos N
Qual Life Res; 2015 Jun; 24(6):1535-44. PubMed ID: 25391489
[TBL] [Abstract][Full Text] [Related]
2. Mapping the cancer-specific EORTC QLQ-C30 to the preference-based EQ-5D, SF-6D, and 15D instruments.
Kontodimopoulos N; Aletras VH; Paliouras D; Niakas D
Value Health; 2009; 12(8):1151-7. PubMed ID: 19558372
[TBL] [Abstract][Full Text] [Related]
3. Predicting SF-6D from the European Organization for Treatment and Research of Cancer Quality of Life Questionnaire scores in patients with colorectal cancer.
Wong CK; Lam CL; Wan YF; Rowen D
Value Health; 2013; 16(2):373-84. PubMed ID: 23538190
[TBL] [Abstract][Full Text] [Related]
4. Testing alternative regression models to predict utilities: mapping the QLQ-C30 onto the EQ-5D-5L and the SF-6D.
Lamu AN; Olsen JA
Qual Life Res; 2018 Nov; 27(11):2823-2839. PubMed ID: 30173314
[TBL] [Abstract][Full Text] [Related]
5. Mapping QLQ-C30 Onto EQ-5D-5L and SF-6D-V2 in Patients With Colorectal and Breast Cancer From a Developing Country.
Yousefi M; Nahvijou A; Sari AA; Ameri H
Value Health Reg Issues; 2021 May; 24():57-66. PubMed ID: 33508752
[TBL] [Abstract][Full Text] [Related]
6. Mapping the Chinese Version of the EORTC QLQ-BR53 Onto the EQ-5D-5L and SF-6D Utility Scores.
Liu T; Li S; Wang M; Sun Q; Chen G
Patient; 2020 Oct; 13(5):537-555. PubMed ID: 32382953
[TBL] [Abstract][Full Text] [Related]
7. Mapping EORTC QLQ-C30 onto EQ-5D for the assessment of cancer patients.
Kim SH; Jo MW; Kim HJ; Ahn JH
Health Qual Life Outcomes; 2012 Dec; 10():151. PubMed ID: 23244763
[TBL] [Abstract][Full Text] [Related]
8. Mapping the EORTC QLQ-C30 and QLQ-H&N35 to the EQ-5D for head and neck cancer: Can disease-specific utilities be obtained?
Beck ACC; Kieffer JM; Retèl VP; van Overveld LFJ; Takes RP; van den Brekel MWM; van Harten WH; Stuiver MM
PLoS One; 2019; 14(12):e0226077. PubMed ID: 31834892
[TBL] [Abstract][Full Text] [Related]
9. Mapping chronic liver disease questionnaire scores onto SF-6D utility values in patients with primary sclerosing cholangitis.
Kalaitzakis E; Benito de Valle M; Rahman M; Lindkvist B; Björnsson E; Chapman R; Kontodimopoulos N
Qual Life Res; 2016 Apr; 25(4):947-57. PubMed ID: 26471264
[TBL] [Abstract][Full Text] [Related]
10. Mapping the cancer-specific QLQ-C30 onto the generic EQ-5D-5L and SF-6D in colorectal cancer patients.
Ameri H; Yousefi M; Yaseri M; Nahvijou A; Arab M; Akbari Sari A
Expert Rev Pharmacoecon Outcomes Res; 2019 Feb; 19(1):89-96. PubMed ID: 30173585
[TBL] [Abstract][Full Text] [Related]
11. Mapping the EORTC QLQ-C30 onto the EQ-5D-3L: assessing the external validity of existing mapping algorithms.
Doble B; Lorgelly P
Qual Life Res; 2016 Apr; 25(4):891-911. PubMed ID: 26391884
[TBL] [Abstract][Full Text] [Related]
12. Mapping the cancer-specific EORTC QLQ-C30 and EORTC QLQ-BR23 to the generic EQ-5D in metastatic breast cancer patients.
Kim EJ; Ko SK; Kang HY
Qual Life Res; 2012 Sep; 21(7):1193-203. PubMed ID: 22012023
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the performance of algorithms mapping EORTC QLQ-C30 onto the EQ-5D index in a metastatic colorectal cancer cost-effectiveness model.
Franken MD; de Hond A; Degeling K; Punt CJA; Koopman M; Uyl-de Groot CA; Versteegh MM; van Oijen MGH
Health Qual Life Outcomes; 2020 Jul; 18(1):240. PubMed ID: 32690011
[TBL] [Abstract][Full Text] [Related]
14. Mapping of the EORTC QLQ-C30 to EQ-5D-5L index in patients with lymphomas.
Xu RH; Wong ELY; Jin J; Dou Y; Dong D
Eur J Health Econ; 2020 Dec; 21(9):1363-1373. PubMed ID: 32960388
[TBL] [Abstract][Full Text] [Related]
15. An assessment of the external validity of mapping QLQ-C30 to EQ-5D preferences.
Crott R; Versteegh M; Uyl-de-Groot C
Qual Life Res; 2013 Jun; 22(5):1045-54. PubMed ID: 22743734
[TBL] [Abstract][Full Text] [Related]
16. Mapping the Memorial Anxiety Scale for Prostate Cancer to the SF-6D.
Erim DO; Bennett AV; Gaynes BN; Basak RS; Usinger D; Chen RC
Qual Life Res; 2021 Oct; 30(10):2919-2928. PubMed ID: 33993437
[TBL] [Abstract][Full Text] [Related]
17. Mapping the Functional Assessment of Cancer Therapy-general or -Colorectal to SF-6D in Chinese patients with colorectal neoplasm.
Wong CK; Lam CL; Rowen D; McGhee SM; Ma KP; Law WL; Poon JT; Chan P; Kwong DL; Tsang J
Value Health; 2012 May; 15(3):495-503. PubMed ID: 22583460
[TBL] [Abstract][Full Text] [Related]
18. Prediction of the SF-6D utility score from Lung cancer FACT-L: a mapping study in China.
Yang Q; Jiang LL; Li YF; Huang D
Health Qual Life Outcomes; 2023 Nov; 21(1):122. PubMed ID: 37964348
[TBL] [Abstract][Full Text] [Related]
19. Use of Bayesian Markov chain Monte Carlo methods to estimate EQ-5D utility scores from EORTC QLQ data in myeloma for use in cost-effectiveness analysis.
Kharroubi SA; Edlin R; Meads D; Browne C; Brown J; McCabe C
Med Decis Making; 2015 Apr; 35(3):351-60. PubMed ID: 25784746
[TBL] [Abstract][Full Text] [Related]
20. Mapping EORTC-QLQ-C30 and QLQ-CR29 onto EQ-5D-5L in Colorectal Cancer Patients.
Ameri H; Yousefi M; Yaseri M; Nahvijou A; Arab M; Akbari Sari A
J Gastrointest Cancer; 2020 Mar; 51(1):196-203. PubMed ID: 30977049
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
